Literature DB >> 9758645

Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats.

M Katoh1, K Egashira, M Usui, T Ichiki, H Tomita, H Shimokawa, H Rakugi, A Takeshita.   

Abstract

It has been shown that nitric oxide (NO) may regulate angiotensin II (Ang II) receptors in vitro. To determine whether the chronic inhibition of NO synthesis upregulates cardiac Ang II receptors in a rat model, we evaluated the in vivo effect of Nomega-nitro-L-arginine methyl ester (L-NAME) on several Ang II receptors and on the expression of AT1 receptor mRNA in heart tissue. The chronic administration of L-NAME to normal rats increased the arterial blood pressure. The number of AT1 and AT2 receptors was increased, with no change in affinity, during the first week of L-NAME administration but returned to control levels after 4 weeks of treatment. The AT1 receptor mRNA was changed parallel to AT1 receptor number. Inflammatory changes (monocyte infiltration and myofibroblast formation) in perivascular areas surrounding coronary vessels and myocardial interstitial spaces were observed during the first week. The immunohistochemistry revealed that myofibroblasts expressed AT1 receptor. AT1 receptor blockade or cotreatment with L-arginine, but not cotreatment with hydralazine, prevented the L-NAME-induced increase in Ang II receptors and inflammatory changes. In conclusion, rat cardiac Ang II receptors are upregulated at an early phase of chronic inhibition of NO synthesis. This may contribute to cardiovascular inflammatory changes in an early phase and to remodeling at the later phase, which occurs after inhibition of NO synthesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9758645     DOI: 10.1161/01.res.83.7.743

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  13 in total

1.  Protective effect of Melothria maderaspatana leaf fraction on electrolytes, catecholamines, endothelial nitric oxide synthase and endothelin-1 peptide in uninephrectomized deoxycorticosterone acetate-salt hypertensive rats.

Authors:  Chinnadurai Veeramani; Khalid S Al-Numair; Govindasamy Chandramohan; Mohammed A Alsaif; Kodukkur Viswanathan Pugalendi
Journal:  J Nat Med       Date:  2012-01-14       Impact factor: 2.343

Review 2.  Angiotensin II and nitric oxide interaction.

Authors:  Marc de Gasparo
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

Review 3.  Pathogenesis and therapeutic implications of cardiorenal syndrome.

Authors:  Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2010-11-23       Impact factor: 2.801

4.  Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in L-NAME-treated rats.

Authors:  Françoise Stanke-Labesque; Gaëlle Hardy; Françoise Caron; Jean-Luc Cracowski; Germain Bessard
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

5.  Endogenous angiotensin II has fewer effects but neuronal nitric oxide synthase has excitatory effects on renal sympathetic nerve activity in salt-sensitive hypertension-induced heart failure.

Authors:  Takehito Kemuriyama; Megumi Tandai-Hiruma; Kazuo Kato; Hiroyuki Ohta; Satoshi Maruyama; Yoshiaki Sato; Yasuhiro Nishida
Journal:  J Physiol Sci       Date:  2009-03-28       Impact factor: 2.781

Review 6.  The therapeutic effect of natriuretic peptides in heart failure; differential regulation of endothelial and inducible nitric oxide synthases.

Authors:  Angelino Calderone
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

7.  Diosgenin improves vascular function by increasing aortic eNOS expression, normalize dyslipidemia and ACE activity in chronic renal failure rats.

Authors:  Jeganathan Manivannan; Elumalai Balamurugan; Thangarasu Silambarasan; Boobalan Raja
Journal:  Mol Cell Biochem       Date:  2013-08-23       Impact factor: 3.396

Review 8.  Cardiorenal Syndrome and Heart Failure-Challenges and Opportunities.

Authors:  Haran Yogasundaram; Mark C Chappell; Branko Braam; Gavin Y Oudit
Journal:  Can J Cardiol       Date:  2019-04-12       Impact factor: 6.614

9.  Renal function in patients with hypertension associated congestive cardiac failure seen in a tertiary hospital.

Authors:  C U Osuji; C U Nwaneli; B J Onwubere; E I Onwubuya; G I Ahaneku
Journal:  Int J Nephrol       Date:  2012-10-10

Review 10.  Management of cardiorenal metabolic syndrome in diabetes mellitus: a phytotherapeutic perspective.

Authors:  Min Kyong Song; Neal M Davies; Basil D Roufogalis; Tom Hsun-Wei Huang
Journal:  J Diabetes Res       Date:  2014-04-13       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.